Novoste to raise $45 million from public offering:
This article was originally published in Clinica
Executive Summary
Novoste plans to raise around $45 million from a public offering of 2.4 million shares at $20 per share. The Norcross, Georgia-based company will use the proceeds for funding ongoing clinical trials, to expand its sales and marketing resources and to continue product development of the Beta-Cath system, which is designed to reduce the incidence of restenosis.